Analytical Framework for Examining the Value of Antibacterial Products. A.6.2 Current Treatment


According to American Thoracic Society/Infectious Diseases Society of America guidelines, patients with no known risk factors for multi-drug resistant pathogens and early onset of disease may receive initial intravenous treatment with antibacterial drugs such as ceftriaxone, levofloxacin, moxifloxacin, ciprofloxacin, ampicillin/sulbactam, or ertapenem, depending on the potential pathogen.

Patients with late-onset disease or other risk factors for infection with multi-drug resistant pathogens should be treated with antibacterial agents likely to cover the suspected etiologies. Possible therapies include an antipseudomonal cephalosporin (cefepime, ceftazidime); an antipseudomonal carbepenem (imipenem or meropenem); a beta-lactam/beta-lactamase inhibitor (piperacillin–tazobactam) plus an antipseudomonal fluoroquinolone (ciprofloxacin or levofloxacin); or an aminoglycoside (amikacin, gentamicin, or tobramycin) plus linezolid or vancomycin.

View full report


"rpt_antibacterials.pdf" (pdf, 1.43Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®